Macrophage migration inhibition factor (MIF) is one of a class of lymphocyte-derived mediator substances (lymphokines) which plays a role in the mechanism of cellular immunity. A variety of other soluble factors produced by non-lymphoid cells have been shown to have effects on macrophage mobility similar to that of MIF. In the present study we demonstrate that one such factor, (MIFv) derived from simian virus 40-infected kidney cells in culture, has several other properties in common with lymphocyte-derived MIF (MIFL). MIFv can be adsorbed bn Sepharose bead columns conjugated with an antiserum prepared against MIFL, demonstrating at least some antigenic similarity. Moreover, MIFv can substitute for MIFL in an in vivo system involving the suppression of cutaneous manifestations of cellular immunity by intravenous injection of the lymphokine. These observations, taken in conjunction with the similarity of the in vitro effect of MIFv and MIFL, and their similar chromatographic behavior, suggest that MIFv and MIFL may be identical molecular species.
A number of soluble, non-antibody mediator substances (lymphokines) may be produced by lymphocytes under various experimental conditions. The classic situation for lymphokine production involves the stimulation of sensitized lymphocytes by specific antigen. In addition, it has been shown that mitogens can induce the production of similar factors by nonsensitized lymphocytes (1, 2) . On the basis of much indirect evidence, it was assumed that thymus-derived lymphocytes (T cells) were the source of lymphokines. It has been recently demonstrated by Yoshida et al. (3) and subsequently confirmed by Rocklin et al. (4) that under appropriate in vitro conditions, bone marrow-derived lymphocytes (B lymphocytes) as well as T lymphocytes can produce the lymphokine migration inhibition factor (MIF). In addition, the prior studies (3) had demonstrated that the soluble mediator of the macrophage disappearance reaction, an in vivo manifestation of cellular immunity, could be produced by B cells as well as T cells.
Substances with lymphokine-like activity are ubiquitous in nature, Thus, a variety of cell types other than lymphocytes can release MIF or MIF-like factors into tissue culture (5, 6) . Similar factors may appear in the serum of either immunized Abbreviations: MIF, migration inhibition factor; MIFv, migration inhibition factor derived from simian virus 40 infected kidney cells in culture; MIFL, migration inhibition factor derived from lymphocytes; AGMK, African green monkey kidney; T cell or T lymphocyte, thymus-derived lymphocyte; B cell or B lymphocyte, bone marrow-derived lymphocyte; SV40, simian virus 40; Lf, limit of flocculation. 1641 animals (7, 8) or patients with various lymphoproliferative disorders (9) . Finally, the infection of a variety of cells by viruses such as mumps and Newcastle disease virus in vitro (10, 11) or in vivo (12) , and simian virus (SV40) in vitro (13, 14) leads to the production of lymphokine-like substances. Thus, the production of these factors seems to represent a general biologic phenomenon.
Mediator substances with similar biologic activity, though obtained from diverse cellular sources, may have strikingly similar physicochemical properties. However, few investigators feel comfortable in labeling them in such a manner as to imply even functional identity. This is most frequently the case in studies of macrophage migration inhibitory factors. Accordingly, we felt it to be of importance to attempt to clarify the relationship between MIF's from different sources.
Recently, we have shown that administration of exogenous MIF-rich lymphocyte culture supernatants into guinea pigs actively immunized to unrelated antigens could suppress delayed skin reactions in those recipients (8) . In an unrelated study, we have demonstrated that it is possible to prepare antisera against culture supernatants obtained from antigenactivated cultures of sensitized lymphocytes. We have shown that those antisera can suppress various lymphokine activities in vitro and in vivo (15) . These two systems, one involving suppressive effects of excess, exogenous lymphokine, and the other involving suppression by specific anti-lymphokine antisera, seemed ideally suited to a study of the relationship of nonlymphocyte-derived MIF to conventional MIF. In the present report, we so characterize a macrophage migration inhibition factor obtained from the infection of monkey kidney cells with SV40 virus.
METHODS AND MATERIALS
Lymphocyte Culture Supernatants. Supernatants with MIF activity were obtained as described previously (8, 15 t % Reduction = (difference in area between skin reactions in experimental and control supernatants area in control) X 100
rations will be called MIFL to distinguish it from the virusinduced factor described below. Similarly, the antigen-reconstituted control will be called ControlL.
Virus-Infected Kidney Cell Cultures. Virus-induced MIF (MIFv) was obtained by inoculating African green monkey kidney (AGMK) cells (GIBCO, Grand Island, N.Y.) with SV40 virus and harvesting supernatants 24 hr later as previously described (13) . Complete monolayers of these cells in 75 cm2 flasks were inoculated with 0.5 ml of undiluted SV40 virus which represents a cytolytic dose [titer: 105-8TCID (tissue culture infectious dose)r,/0.1 ml]. The cultures were incubated at room temperature for 20 min. After this period, 25 ml of Eagle's minimal essential medium supplemented with 2% fetal calf serum were added and the flasks incubated at 37°. Control flasks were incubated initially with 0.5 ml of medium and then treated in a similar way. After 24 hr of incubation, the supernatants from the infected and the control flasks were removed, UV-irradiated and centrifuged at 1850 X g for 30 min. Control supernatants (Controlv) were reconstituted with UV-irradiated virus.
Sephadex G-100 Gel Filtration. Lyophilized supernatants were dissolved in cold distilled water to achieve a 30-fold concentration of the initial supernatant fluid. Any resulting insoluble material was removed by centrifugation. Such removal had been confirmed not to reduce significantly the MIF activity in the supernatant. Three milliliters of the concentrated supernatant was applied on Sephadex G-100 columns (2.5 X 50 cm) and eluted with 0.1 M phosphate buffered saline. Eluates were collected as 3 ml aliquots. MIF-containing fractions were pooled, as were the corresponding fractions obtained from control supernatants. These pools were obtained from fractions containing material in the molecular weight range of 45,000-67,000.
Anti-Lymphokine Antiserum. The preparation used in these studies was one which had been previously described and characterized (15) . It was produced by a two-stage procedure.
In brief, MIFL and control supernatants were obtained from guinea pig lymphocyte cultures. They were fractionated on Sephadex G-100. Fractions of control supernatants corresponding to active fractions from the MIF-rich material were used to immunize rabbits. The anti-control antibody so obtained was conjugated to agarose beads. The MIF-rich Sephadex fractions were passed through this immunoadsorbent column to remove materials corresponding to those found in control supernatants and which could react with the anticontrol antibody. The eluted, MIF-rich fraction was concentrated and used to immunize a second group of rabbits. The anti-lymphokine antibody so obtained was found capable of suppressing the activity of MIFL, macrophage chemotactic factor, and skin reactive factor. In that study (15) it could also suppress delayed hypersensitivity reactions in vivo in actively immunized guinea pigs.
Preparation of Immunoadsorbents. The anti-lymphokine and anti-control antisera described above were bound to agarose beads (Sepharose 2B) activated by cyanogen bromide as described previously (15) . Activated agarose beads (250 ml packed volume) were reacted with 50 ml of either antiserum at 40 for 18-24 hr. They were washed with 10 volumes of phosphate-buffered saline, 10 volumes of acetic acid, 2 volumes of 2% fetal calf serum, and 10 volumes of phosphate-buffered saline in that order. The antiserum-conjugated beads were used as immunoadsorbents within 24 hr of such preparation.
Migration Inhibition Assay. For experiments to determine the effect of anti-lymphokine sera on MIFv and MIFL activity, macrophage migration inhibition assays were performed as we have described previously (8, 15) . The area of migration in the medium containing test samples was compared with that in the medium containing control samples. The migration index was calculated as described previously (16 (1975) and 79.2% when MIFv is used. The control fluids, which were reconstituted with either antigen or virus, as described in Methods and Materials, were without significant effect.
Effect of anti-lymphokine serum on MIFv and MIFL Immunoadsorbent columns containing either anti-lymphokine or anti-control antibody were prepared as described above. As already indicated, these antisera were prepared against supernatant fluids obtained from antigen-activated and control lymphocyte cultures. Five milliliters each of MIFvor MIFL-containing supernatants, or their respective controls, were passed through the immunoadsorbent columns packed with 30 ml of either anti-control conjugated or antilymphokine conjugated agarose beads. After incubation at room temperature for 60 min, each column was eluted by 50 ml of RPMI 1640. The eluates were lyophilized and reconstituted to the original volume (5 ml each), and then dialyzed against RPMI 1640. These preparations were supplemented with 20% normal guinea pig serum and tested for MIF activity. The results are shown in Table 2 . Adsorption with Sepharose beads conjugated with anti-control antibody had no effect on the activity of either the MIFL or the MIFv-containing preparations. The migration indices of 63.2 and 69. It should be noted that the calculations of migration indices in these experiments are always made relative to the migration of macrophages in the appropriate control fluid which had been passed through the appropriate Sepharose column. In any case, passage of any control fluid through any column had no effect on its ability to support macrophage migration.
DISCUSSION
Viral infection of a variety of cells in vitro and in vtivo leads to the production of substances with lymphokine-like activity (10) (11) (12) (13) (14) . Such substances include macrophage migration inhibition factors, neutrophil and macrophage chemotactic factors, and skin reactive factors. Recently, we have reported (13) that SV40 virus can induce the production of an MIFlike factor by AGMK cells, in the absence of the concomitant appearance of other lymphokine-like activities. Sephadex chromatography of active supernatants revealed the MIF activity to be in fractions corresponding to a molecular weight range of 45,000-67,000 and in another fraction corresponding to an approximate molecular weight of 12,000. This distribution corresponds precisely to that of conventional, lymphocyte-derived MIFL (17) .
The exact relationship of the virus-derived factor (MIFv) to MIFL is difficult to determine because of the lack of precise biochemical characterization data for either. The issue is of importance, since the wide range of experimental settings in which lymphokine and lymphokine-like activity can be detected suggests that these factors may be ubiquitous in nature, and that their biologic role is not confined to the immunologic system. These factors, for the most part, exert their effect on various inflammatory cells. If these agents from different cel- tionally identical, this identity will provide a unifying framework for the various aspects of host defense which involve the inflammatory system.
In the present study we have compared MIFL and MIFv in two ways. First, we have shown that MIFv is as capable as conventional MIFL in suppressing cutaneous manifestations of delayed hypersensitivity when injected intravenously. The mechanism of this immunosuppressive effect is not clear, but it is thought to involve activation and immobilization of macrophages systemically, so that they are pre-empted from participating in the cutaneous reaction (8) . In any case, this experimental procedure demonstrates that MIFv shares, in vivo as well as in vitro, properties with MIFL.
The second comparison of MIFV and MIFL made here is the demonstration that both may be removed from supernatants by passage through an immunoadsorbent column containing antibody raised against MIFL. This antigenic cross-reactivity between factors obtained from widely different sources (antigen-activated lymphocytes versus virusinfected kidney cells) suggests at least partial chemical homology.
The present study provides one possible explanation for the intriguing observation that many viral infections lead to a depression of the expression of preexisting delayed hypersensitivity (18, 19) . In one of these studies (18) , it was shown that sensitivity could be transferred from infected animals with depressed skin reactivity to normal animals, demonstrating that there was no defect in the function of specifically sensitized lymphocytes. Since exogenous MIF can suppress skin reactivity, it seems likely that high circulating levels of endogenous virus-induced MIF could do so as well. The demonstration that mumps virus can induce MIF in vivo as well as in vitro (11, 12) is evidence for this mechanism of suppression. However, further work is required correlating cutaneous reactivity, serum MIF, and in vitro manifestations of cellular immunity during the course of viral infections.
The results reported here lend further support to the view that various substances with a particular lymphokine-like activity may have chemical as well as functional properties in common, even though derived from diverse sources. It is tempting to postulate that the ability to produce these agents lular sources can be shown to be chemically as well as funcrepresents one of the most primitive self-defense mechanisms and that cellular immunity, to the extent that it is dependent upon lymphokine production, represents a subsequent evolution of that system. This study was supported by N.I.H. Grants AI-12225 and AI-12477.
